NASDAQ
46.42USD
+1.06 (+2.34%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.2B
P/E
—
EPS
—
Beta
0.94
52W range
8.73-71.5
Day range
45.02–48.10
Open
46.35
Prev close
45.36
Volume
1.8M
Avg volume
1.8M
Dividend
0.00
IPO
2014-02-05
https://www.zacks.com/stock/news/2955847/is-qure-stock-attractive-after-its-rally-rich-valuation-and-hold?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2955847 · 7/17/2026+0.20
https://www.cnbc.com/2026/06/25/chan-zuckerberg-biohub-rare-disease-funding.html · 6/25/2026+0.00
https://www.globenewswire.com/news-release/2026/06/24/3316560/0/en/uniQure-Announces-Pricing-of-Upsized-225-Million-Public-Offering.html · 6/24/2026+0.30
https://www.zacks.com/stock/news/2940441/qure-soars-as-fda-backs-amt-130-data-for-accelerated-approval?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2940441 · 6/19/2026+0.80
https://www.cnbc.com/2026/05/12/trump-fda-commissioner-marty-makary-out.html · 5/12/2026-0.30
https://www.newsfilecorp.com/release/292201/Bronstein-Gewirtz-Grossman-LLC-Urges-uniQure-N.V.-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm · 4/13/2026-1.00
https://www.prnewswire.com/news-releases/qure-investors-have-opportunity-to-lead-uniqure-nv-securities-fraud-lawsuit-with-the-schall-law-firm-302739987.html · 4/13/2026-0.80
https://www.newsfilecorp.com/release/291975/IT-SHAREHOLDER-REMINDER-Faruqi-Faruqi-LLP-Reminds-Gartner-IT-Investors-of-Securities-Class-Action-Deadline-on-May-18-2026 · 4/12/2026+0.00
https://www.newsfilecorp.com/release/291738/ATTENTION-GOSS-INVESTORS-Contact-Berger-Montague-About-a-Gossamer-Bio-Inc.-Class-Action-Lawsuit · 4/9/2026+0.00
https://www.globenewswire.com/news-release/2026/04/04/3268187/32716/en/QURE-9-DAY-DEADLINE-ALERT-Hagens-Berman-Updates-uniQure-QURE-Investigation-Following-Public-FDA-Rebukes-and-Allegations-of-Distorted-Data.html · 4/4/2026-1.00
https://www.globenewswire.com/news-release/2026/03/31/3266232/32716/en/QURE-INVESTOR-ALERT-Hagens-Berman-Updates-uniQure-QURE-Investigation-Following-Public-FDA-Rebukes-and-Allegations-of-Distorted-Data.html · 3/31/2026-1.00
https://www.prnewswire.com/news-releases/uniqure-nv-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302727693.html · 3/28/2026-1.00
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
